Hemophilia Clinical Trial
Official title:
What is the Feasibility, Acceptability and Sensitivity of the iSTEP Exercise Test in Boys With Haemophilia?
This study will be used to assess the feasibility and sensitivity of using the iSTEP, to
assess exercise capacity in boys with haemophilia.
The feasibility criteria to be explored includes:
1. Recruitment to target number or better
2. The test procedure is completed within an allocated time (1-2 hours) and by 90% of
participants without serious adverse events
3. 90% of participants achieve a sufficient exercise response (85% maximum heart rate
(HRmax))
4. Calculation of estimates of minimum clinically important differences and variability for
sample size calculations and responsiveness to severity of haemophilia and orthopaedic
status The iSTEP exercise test will be compared to a more commonly used exercise test
the modified shuttle walk test (10m- MSWT). Muscle strength (using myometry) will also
be tested and compared to exercise performance for any relationships. Physical activity
levels will also be assessed to obtain some baseline measurements of physical activity
levels in this patient population, which are currently not very well known. The
overarching aim of this current study is also to establish a robust and sensitive
exercise test and to gain an understanding of the effects of physical activity levels
and muscle strength on exercise capacity in this population.
Identification of potential participants Eligible participants will be identified from the
clinical patient database in the Haemophilia Centre at Great Ormond Street Hospital (GOSH)
for Children NHS Trust. Potential participants will then be randomly selected. A simple
randomisation approach will be employed using a computer random number table to select
potential participants from the database. The parents / legal guardians will then be
approached initially by the investigator via telephone to provide a brief verbal explanation
of the research study and ask if they would be happy to receive a patient information sheet
prior to their next clinic appointment. Should they be interested in participating in the
study they will receive, by post, the PIS (one for parents and a separate age appropriate
version for children) at least one week prior to their next clinic appointment. This will
allow for a 'cooling-off' period of a minimum of one week for the potential participants. The
researcher will then be available for questions by telephone or at the participant's next
clinic appointment.
For the normal healthy control exercise test comparison population, data will be obtained
from the existing iSTEP healthy control data collected as part of the iSTEP study from
children in primary schools in London. This sample of 30 participants will be matched to the
haemophilia group in terms of sex, age, body mass and stature.
Participant Recruitment
Consent of participants:
Most study recruits will be unable to give consent to participate due to their age. If the
family have indicated that they are interested in participating in the study then at an
agreed time (likely the next clinic appointment) one of the investigators from the research
team will meet with the child participant and parent / legal guardian to complete the consent
and assent forms as appropriate. The investigator will further explain the study procedures
to the parent and child, why they are being asked to consider to be a part of the study and
the associated risks and benefits of being included. The parent and child will then be given
an opportunity to ask any further questions. The child/parent/legal guardian will then be
asked to confirm if they agree to take part in the study. If consent is agreed a parental
consent form will be completed by the parent/guardian and a copy will be provided. If the
child assents then they will be asked to sign an assent form. If at any point during the
study process the parent/guardian does not consent to inclusion in the study or the child
withdraws their assent, then any data collected will be destroyed. Any decision to refuse or
withdraw from the study will in no way influence the services that they receive.
Discussion with parents about the project will be undertaken with the child present. Once the
child's parent/guardian has given consent, the child must also indicate that they do not
object to participating in the research activity and understand what is involved. This
participant 'assent' will be sought from participants in concordance with the legal
requirements in England as set out in the following documents:
- Children Act 1989
- Medical Research Council (2004). MRC Ethics Guide: Medical research involving children.
Version 3.2 May 2007 A signed participant assent form will be completed and a copy will
be provided (Appendix 3).
The participant's medical team will be informed that they have volunteered to participate in
this study, through verbal handover and documentation within the medical notes. Non-clinical
members of the research team will only be able to access the participant's medical records
once signed consent of this specific item has been provided.
The evaluation of the recruitment process will include recording of percentages of refusals
to consent and stated reasons, as part of the feasibility aspect of this study. This will
inform the design of future studies with this group with regards to approach and recruitment
protocols. Confidentiality Data collection and storage will be undertaken in accordance with;
The Caldicott Principles, Data Protection Act 1998 and Confidentiality: NHS Code of Practice
2003. The non-clinical members of the research team will only access data once consent has
been provided from the parent/s. To ensure participant's confidentiality, data will be made
anonymous by allocating a study participant number to identify their data. The research team
will be the only ones to know the identity of each individual against his or her study
number. All data will be recorded on a GOSH Trust computer under an electronic folder with
restricted access for the investigators involved in the trial, electronic files will be
encrypted and password protected. During the phases of data collection and analysis, only the
chief investigator and research team will have access to the raw data and research findings.
On completion of the research, data will be summarised and de-identified findings will be
disseminated through publication in an appropriate professional journal and/or conference
presentation.
Should a participant experience exacerbation to any joint pain during the exercise trial
process, they will be able to stop and rest at any time. Should they feel unable to continue
they will be able to withdraw from the study. The iSTEP is an exercise test that uses a step,
which is tailored to the participant's height. It becomes incrementally more difficult every
2 minutes over the 10 minutes of the test, as the participant has to step up and down in time
with a metronome (on audio track). The test ends when the participant is too tired to
continue (see iSTEP protocol below), falls out of time with the metronome for stepping or at
the end of the 10 minutes (that includes all 5 levels). Heart rate is taken at rest (before
test), immediately afterwards and 3 minutes after the test.
The 10m- Modified Shuttle Walk Test (10m-MSWT) is a fitness bleep test that is also
incremental. There are 25 levels, each level lasts 1 minute. The audio track guides the test,
the bleeps at the beginning of the test are spaced widely apart (e.g. 20seconds to walk 10m
in the first level). The time between bleeps becomes shorter every minute so that the
participant will have to start fast walking then jogging at approximately level 6. At level
10 onwards the participant will need to run to keep in time with the bleeps. The test
finishes when the participant is unable to continue due to , fatigue, breathlessness, or is
unable to keep up with the bleeps. Heart rate is taken at rest, immediately after the test
and 3 minutes after the test is finished (protocol below). Muscle myometry: uses a device to
measure muscle power and is commonly used in research. The participant will be asked to push
against resistance as strongly as they are able and the maximal power is calculated by the
device (protocol below). Accelerometry: Activity will be measured using the ActiGraph GT3X,
an accelerometer that measures volumes and patterns of activity. The ActiGraph has been
extensively validated in children. A 15-second sampling epoch will be selected in order to
optimize the ability to capture the sporadic nature of children's activity. Children will be
asked to wear the accelerometer on an belt on the right hip for seven consecutive days during
all waking hours. Accelerometers will be provided to families on the testing day and they
will be asked to return it as soon as possible after the monitoring period (7days) using a
supplied pre-paid envelope.
PROTOCOLS:
iSTEP Protocol Preparation
- The explanation to the participant is located on the pre-recorded audio track
- They will be required to step up and down in time with a metronome.
- The height of the step is standardised for each child and will be based on
approximately 50% of the length of the child's fibula.
- There is a bell to start. Thereafter the audio-track emits a metronome bleep at set
speeds for 2 minutes at regularly spaced intervals.
- After every 2 minutes, the speed of stepping is increased by a small increment, so the
participant steps progressively faster; the change in incremental stepping speed is
indicated by a bell bleep.
- The first speed of walking is referred to as LEVEL 1, the second as LEVEL 2, and so on.
Each level lasts for 2 minutes and the audio-recording continues for 5-levels (10
minutes in total). Each level contains a number of steps the number of which is dictated
by the speed of that level.
- The first level reciprocally stepping up and down at a rate of 36
- To help the participant establish the first very slow speed of stepping, the operator
steps alongside for the first time.
4. End point of the test
- If the participant completes the 10 minutes (5 levels of the test) the test is
completed.
- The end point of the test may be determined by the operator when:
- Inability to maintain rhythm with the metronome, progressive speeding up and
slowing down for >30 seconds
- Loss of coordination
- Light headedness
- Extreme exhaustion
- Sudden pallor
- Undue signs of distress including severe wheezing or chest pain 10M MODIFIED
SHUTTLE WALK TEST (25 LEVELS) PROTOCOL GENERAL INSTRUCTIONS Similar guidance to
participants as provided for iSTEP Starting the test
- There is a triple bleep to start. Thereafter the audio-track emits a single bleep at
regularly spaced intervals. The participant should aim to be at the opposite end to the
start by the time the bleep sounds.
- After first minute, the speed of walking is increased by a small increment, so the
participant walks progressively faster; the change in incremental speed is indicated by
a triple bleep.
- The first speed of walking is referred to as LEVEL 1, the second as LEVEL 2, and so on.
Each level lasts for 1 minute and the audio-recording continues for 25-levels. Each
level contains a number of shuttles (10m in length), the number of which is dictated by
the speed of that level. End point of the test
- The end point of the test may be determined by the participant:
When he or she becomes too breathless to maintain the required speed
• The end point of the test may be determined by the operator when: Undue signs of distress
including severe wheezing or chest pain Failure of the patient to complete the shuttle in the
time allowed. This test takes approximately 10-15 minutes, dependant on participant. MUSCLE
MYOMETRY PROTOCOL A hand held dynamometer will be used to record the force produced by a
maximum voluntary isometric contraction (MVIC) of the knee extensors, and ankle dorsi and
plantar flexors. This test will take 5-10 minutes as part of their routine clinical
examination. The total time required of the participant, on top of the routine clinic visit
will be approximately 1 hour 30 minutes.
A14-1. In which aspects of the research process have you actively involved, or will you
involve, patients, service users, and/or their carers, or members of the public? Design of
the research Management of the research Undertaking the research Analysis of results
Dissemination of findings None of the above Give details of involvement, or if none please
justify the absence of involvement.
Parents and children were approached to provide comments and changes to the PIS forms in
wording and design. In addition they provided opinion upon the potential burden of the of
undertaking the testing. They reported that they did not feel the testing protocol sounded
too onerous on top of normal clinical assessment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05617209 -
In Vitro Correction of Thrombin Generation by Concizumab (Anti-TFPI) for Severe Hemophilia Patients
|
||
Completed |
NCT05039008 -
Restricting Blood Flow in Improving Muscle Strength in Patients With Hemophilic Arthropathy
|
N/A | |
Recruiting |
NCT04398628 -
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
|
||
Completed |
NCT02546622 -
ATHN 2: Factor Switching Study
|
||
Unknown status |
NCT02433782 -
Myofascial Therapy in Patients With Hemophilic Arthropathy
|
N/A | |
Completed |
NCT02165462 -
Bilateral Deficit Phenomenon in Patients With Haemophilic Arthropathy
|
N/A | |
Unknown status |
NCT02165592 -
Assessment of Proprioceptive and Functional Characteristics in Patients With Hemophilia
|
N/A | |
Terminated |
NCT02586012 -
Weight-based Dosing in Hemophilia A
|
Phase 2 | |
Completed |
NCT01232634 -
Validation of Ultrasound as a Diagnostic Tool for Assessment of Hemophilic Arthropathy of Knees and Ankles
|
Phase 2 | |
Completed |
NCT05104164 -
Self-myofascial Release in Hemophilic Ankle Arthropathy
|
N/A | |
Terminated |
NCT01191372 -
First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients
|
Phase 1 | |
Completed |
NCT05173129 -
Posture Analysis for Patients With Haemophilia
|
N/A | |
Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
Withdrawn |
NCT03996486 -
Study to Test the Safety of an Investigational Drug Given Repeatedly to Adult Men With Severe Hemophilia
|
Phase 1 | |
Completed |
NCT01708564 -
A Phase I Safety, Pharmacokinetics and Pharmacodynamics Study of Recombinant Factor VIIa in Adult Patients With Hemophilia A or B
|
Phase 1 | |
Completed |
NCT03842605 -
Efficacy of Strength Training in Improving Elbow Range of Motion and Function in Adults With Hemophilia
|
N/A | |
Completed |
NCT05549843 -
Manual Therapy in the Treatment of Hemophilic Arthropathy of the Ankle
|
N/A | |
Recruiting |
NCT06010953 -
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT05027230 -
A Safety and Efficacy Study of STSP-0601 in Adult Patients With Hemophilia A or B With Inhibitor
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06014320 -
Alterations in Coagulation Factor Levels in Patients With End Stage Liver Disease
|